Czech authorities withdraw Turkish slimming tea after sibutramine detection
Czech authorities have stopped sales and ordered the withdrawal of a Turkish slimming herbal tea after official controls detected sibutramine. The EU’s RASFF system classified the risk as serious, although no illnesses have been officially recorded.
Official controls uncover sibutramine
Czech authorities have ordered a Turkish-origin slimming herbal tea off the market after official controls detected sibutramine, an undeclared appetite suppressant associated with serious cardiovascular risks. According to Sözcü and Yeni Alanya, the measure includes stopping sales and withdrawing the affected product from shelves in Czechia.
The notification entered the European Union’s Rapid Alert System for Food and Feed, or RASFF, on 20 July 2026. The European Commission confirmed the notification, and the product was recorded as food within the category covering dietetic foods, food supplements and fortified foods. The available reports do not identify the manufacturer, brand, batch, shipment size or distribution network.
Risk classified as serious
RASFF classified the product’s risk level as serious. Sözcü reported that the notification was treated as information requiring attention, while the preventive action recorded in the system covered a sales halt and market withdrawal. No illness or affected consumer had been officially recorded in connection with the tea at the time described by either publication.
Sibutramine suppresses appetite and was previously used for weight reduction. Scientific research linked the substance to increased risks of heart attack, stroke and other severe cardiovascular effects. Its use is not permitted in the European Union, Turkey and numerous other markets, according to the source reports. Its presence in a product presented as herbal therefore raises both food-safety and labelling concerns.
Implications for Turkish supplement suppliers
The incident exposes Turkish manufacturers and exporters of herbal slimming products to closer scrutiny of formulations, ingredient declarations and batch testing. Because the product was found during Czech market surveillance rather than through a reported illness, the case also illustrates how destination-country controls can detect undeclared pharmaceutical substances after goods have entered retail channels.
For importers and distributors, the absence of publicly reported brand and batch details limits the immediate ability to assess whether related inventory is affected. Traceability records, supplier documentation and independent laboratory testing become particularly important when products make rapid-weight-loss claims or are sold through lightly supervised online channels. Yeni Alanya cited experts warning that products marketed as entirely herbal can contain illegally added chemical ingredients intended to accelerate weight loss. The withdrawal may therefore prompt additional checks on comparable Turkish supplements, although the available RASFF information does not establish a wider problem or identify other products.
